Towards Healthcare
Retinal Biologics Market Size Captures USD 53.61 Billion by 2034

Retinal Biologics Market Size, Regional Insights and Strategic Developments

According to market projections, the global retinal biologics market, valued at USD 25.02 billion in 2024, is anticipated to reach USD 53.61 billion by 2034, growing at a CAGR of 7.92% over the next decade. The growing geriatric population drives the market’s growth.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Retinal Biologics Market Assessment

  • Overview
  • Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

North America Retinal Biologics Market Assessment

  • Overview
  • North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe Retinal Biologics Market Assessment

  • Overview
  • Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific Retinal Biologics Market Assessment

  • Overview
  • Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Latin America Retinal Biologics Market Assessment

  • Overview
  • Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East & Africa Retinal Biologics Market Assessment

  • Overview
  • Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • VEGF-A Antagonist
    • TNF-A Inhibitor
  • Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
    • Macular Degeneration
    • Diabetic Retinopathy
    • Uveitis
    • Others
  • Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Company Profiles

  • Santen Pharmaceutical Co., Ltd (Japan)
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • AbbVie Inc. (U.S.)
  • Aurobindo Pharma (India)
  • Bayer AG (Germany)
  • Bayer AG (Germany)
  • Fresenius Kabi AG (Germany)
  • AstraZeneca (U.K.)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co Inc. (U.S.)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Amgen Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Kodiak Sciences Inc. (U.S.)

Conclusion & Recommendations

  • Insight Code: 5166
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The human immune system is able to identify biologics quickly and able to mount a faster immune response.

While drugs are completely synthesized from molecular compounds with the help of chemical reactions, biologics are produced or extracted from biological entities.

FDA, World Health Organization (WHO), Centers for Medicare & Medicaid Services (CMS), National Bureau of Statistics of China, National Library of Medicine, National Institutes of Health.